Association

Parounak Zelveian

...
Parounak Zelveian

CURRICULUM VITAE

PROF. PAROUNAK H. ZELVEIAN, MD, PH.D, FESC
Director of the Institute of Cardiology named L.A. Hovhannisyan
Chief Cardiologist of Yerevan City
Past President of Armenian Cardiologist’s Association
Past President of Armenian Medical Association
 

Paruyr Sevak St. 5, Yerevan 375044, Armenia
Tel: +374 (10) 288-606; +374 (10) 288-550
Fax: (+37410) 288-502
E-mail: zelveian@armeda.am or 
zelveian@hotmail.com
www.cardio.am

Date and Place of Birth: September 26, 1966, Yerevan, Republic of Armenia
Nationality: Armenian
Citizenship: Republic of Armenia
Sex: Male

Education and Degrees:

2007 European Society of Cardiology Educational Course: The everyday challenge of prevention, European Heart House, Sophia Antipolis Cedex, France.
2003 European Society of Hypertension Summer School, Ystad, Sweden.
2003 World Heart Federation’s International Teaching Seminar on Cardiovascular Disease Epidemiology and Prevention, Pearson College of the Pacific, Victoria, British Columbia, Canada.
2002 American Heart Association’s Hypertension Summer School, Williamsburg, VA, USA.
1997-2000 Fellow at the Department of Arterial Hypertension of the Institute of Clinical Cardiology of Cardiology Research Complex, Moscow, Russia. (Diploma of the Candidate of Medical Science (Ph.D) for the thesis: «Nocturnal profile of blood pressure and it’s peculiarity in mild to moderate essential hypertensives with sleep-disordered breathing», KT № 018621).
1993-1997 Residency at the Department of Arterial Hypertension of the Institute of Clinical Cardiology of Cardiology Research Complex, Moscow, Russia. Diploma of Doctorate of Cardiology Health with Honors, № 01-97.
1987-1993 Student of the Yerevan State Medical Institute after Mkhitar Heratsi, Yerevan, Armenia. (Diploma of Doctoring of General Medicine (MD) with Honors, № 005574)
1973-1983 General school №67 after E. Charents, Yerevan, Armenia. (Graduated with score 5/5)

Work experience:

2006-2013 Vice director of the Institute of Cardiology on Science
2013-2015 Director of the National Institute of Health
2015-2019 Director of the Center of Preventive Cardiology
2017-2019 Vice director of the Institute of Cardiology
2019 till now Director of the Institute of Cardiology

Awards and Scholarships:

1990-1993 M. Melik-Adamyan Scholarship for Academic Excellence, Yerevan, Armenia.
2000 1st prize and Honor Diploma as a «Best Young Scientist in Nomination Cardiology» in 7th Russian National Congress, Moscow, Russia.
2001 Honor Diploma, National Academy of Since of Republic of Armenia.
2001 Award after Edmond Keosayan (Honor Diploma), Yerevan, Armenia. 
2003 Honor Diploma, Ministry of Health of Republic of Armenia.
2005 Honor Diploma, National Academy of Since of Republic of Armenia.
2006 Fellowship of European Society of Cardiology

Research activities:

Main research interests are related to hypertension, epidemiology and preventive cardiology and his current projects are focused on hypertension, ischemic heart disease, chronic heart failure and sleep breathing disorders. Principal Investigator in several multicenter II-IV phase studies and National Coordinator of «MHM», «SIGNIFY», «QUALITY», «QUALIFY», «TRIPLE-A», «REALITY», «MMM-17», «TELE-REMETRI», «MMM-18», «MMM-19», «ESH BP CONTROL», «PRECIOUS» and other studies. Reviewer for a number of national and international peerreviewed journals, member of several national and international journals Editorial Board. Currently Chief Editor of the Scientific Medical Journal of the National Institute of Health of the Ministry of Health of the Republic of Armenia. Books and/or chapters: 22

Publications: (listed until January 2020)
Articles: 158
Abstracts: 267

Membership in Professional Organizations:

  • Armenian Medical Association (Founder and Past President);
  • Armenian Cardiologists Association (Past President);
  • Armenian Society on Hypertension (The President);
  • Eurasian Cardiologists Association (Board Member);
  • European Society of Cardiology (Fellow);
  • European Association for Cardiovascular Prevention & Rehabilitation (National Coordinator);
  • International Society of Hypertension;
  • European Society of Hypertension;
  • American Society of Hypertension;
  • American Heart Association (Council for High Blood Pressure Research);
  • European Sleep Research Society;
  • American Academy of Sleep Medicine;
  • World Association of Sleep Medicine.

Languages: Native language Armenian, fluent in Russian and English.
Interests: Classical and Jazz music, theater, literature.

EXPERIENCE IN CLINICAL TRIALS:

  • 2008 Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patients with stable angina pectoris. A 6-week randomised double-blind parallel group international multicentre study. Principal Investigator. Clinical Phase: III, Completed
  • 2010 Bioequivalence study of Enalozid® Forte (Enalapril + Hydrochlorothiazide) tablet («Farmak», JSCУ) and Co-renitec ® (Enalapril + Hydrochlorothiazide) tablet («Merck Sharp & Dohme B.V.») in healthy, adult volunteers. Principal Investigator. Clinical Phase: I, Completed
  • 2010 Bioequivalence study of Ursomaks 250 mg capsule («Farmak», JSCУ) and Ursofalk® 250 mg capsule («Dr. FALK PHARMA», GmbH) in healthy, adult volunteers. Principal Investigator. Clinical Phase: I, Completed
  • 2011 Randomized, Double-Blind, Multi-center Study Comparing 15 g Cross-linked Polyelectrolyte (CLP) versus Placebo in Heart Failure Patients with Chronic Kidney Disease. Principal Investigator. Clinical Phase: II, Completed
  • 2012 A pilot bioequivalence study of Hydrochlorothiazide 12.5 mg capsule (Lannett Company Inc.) and Microzide 12.5 mg capsule (Watson Labs) in 12 healthy, adult subjects under fasting conditions. Principal Investigator. Clinical Phase: II, Completed
  • 2011 Effects of Ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind Placebo-controlled international multicentre study. Study assessInG the morbi-mortality beNefits of the If inhibitor Ivabradine in patients with coronary artery disease (SIGNIFY). National Coordinator. Principal Investigator. Clinical Phase: III, Completed
  • 2015 Safety and efficacy of fixed dose combination of Indapamide SR/Amlodipine in single-pill versus free dual therapy at the same dose over 12-week of treatment, with conditional titration based on the blood pressure control, in patients with mild to moderate uncontrolled essential hypertension. An international, multicentre, randomised, open-label study. National Coordinator. Principal Investigator. Clinical Phase: III, Completed
  • 2016 Losartan (Lorista®) and Fixed-Dose Combination of losartan and hydrochlorothiazide (Lorista® H, Lorista® H100, Lorista® HD) – its efficacy, safety and influence on metabolic parameters in hypertensive patients. Principal Investigator. Clinical Phase: IV, Completed
  • 2019 Fixed-Dose Combination of Perindopril/ Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (CoAmlessa®) – Contribution to Management in newly diagnosed and uncontrolled hypertensive patients (PRECIOUSS study). Interventional, open-label, prospective, international, multi-centre clinical trial. National Coordinator. Principal Investigator. Clinical Phase: IV, Completed
  • 2020 Clinical validation of the brachial blood pressure measuring device Withings BPM Connect according to “the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertesion/International Organization for Standardization (AAMI/ESH/ISO)” in the pregnant population. National Coordinator. Principal Investigator. Clinical Phase: IV, Completed
  • 2020 NATriuretic Response to expansion and dIUretics in huMans with Heart Failure (NATRIUM-HF). National Coordinator. Principal Investigator. Clinical Phase: IV, Ongoing
  • 2020 Clinical validation of the brachial blood pressure measuring device Withings BPM Connect according to “the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertesion/International Organization for Standardization (AAMI/ESH/ISO)” in the general population. National Coordinator. Principal Investigator. Clinical Phase: IV, Ongoing
  • 2020 Phase 3b, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis. Principal Investigator. Clinical Phase: III, Ongoing

Download